SYNEOS HEALTH UK LIMITED

DelveInsight's report on Neurotrophic Keratitis Market (2020-2034) covers epidemiology, market trends, key companies (Oyster Point Pharma, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, ReGenTree, BRIM Biotechnology), therapies (OC-01, REC 0559, CSB-001, RGN-259, BRM424, cenegermin-bkbj, Udonitrectag, RGN-259), and market dynamics in the US, EU4, UK, and Japan.

Placeholder text for elements like text, images, lists, etc.

Suspicious activity violating TipRanks' Terms of Use detected, including excessive page views or use of scraping tools. Account typically reactivates within 24 hours; contact support if still disabled.

CytoDyn Inc. engages Syneos Health as CRO for Phase II oncology trial evaluating leronlimab in relapsed/refractory micro-satellite stable colorectal cancer. Trial to start screening patients in early 2025.

CytoDyn Inc. engages Syneos Health for Phase II oncology trial evaluating leronlimab in relapsed/refractory micro-satellite stable colorectal cancer. Syneos Health, a leading biopharmaceutical solutions organization, leverages advanced data analytics and AI/ML capabilities to improve outcomes in clinical development and commercialization.

Emerging biopharma companies must prioritize adaptability in commercialization strategies to accelerate global expansion. Early globalization planning, preliminary brand development, and data-driven market decisions are crucial. Lean launch strategies and leveraging outsourcing partners like Syneos Health can mitigate risks and ensure flexibility. Success stories demonstrate the effectiveness of adaptive commercialization playbooks in navigating market complexities.

OBI-888, a humanized monoclonal IgG1 antibody targeting Globo H, was evaluated in a Phase I–II study for advanced solid tumors. The study found OBI-888 to be safe and well-tolerated, with no maximum tolerated dose (MTD) reached and low incidence of adverse effects. Disease stabilization was observed in 28.6% and 20% of patients in Parts A and B, respectively, suggesting a cytostatic effect. Antibody-dependent cell-mediated cytotoxicity (ADCC) was induced after each OBI-888 dose, indicating ADCC as a potential mechanism of action. However, overall complement-dependent cytotoxicity (CDC) activity was low. Given the limited antitumor activity despite prolonged disease stabilization in some patients, further development of OBI-888 is not planned.